Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 3.2%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) fell 3.2% during trading on Monday . The company traded as low as $27.10 and last traded at $27.10. 8,736 shares were traded during mid-day trading, a decline of 95% from the average session volume of 190,487 shares. The stock had previously closed at $28.00.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, August 12th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Wedbush dropped their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Finally, Robert W. Baird initiated coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $44.71.

Dianthus Therapeutics Stock Performance

The firm has a market capitalization of $817.40 million, a P/E ratio of -4.78 and a beta of 1.85. The stock has a 50 day moving average of $27.91 and a 200-day moving average of $26.19.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The business had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $236,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Dianthus Therapeutics by 281.9% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after buying an additional 29,159 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $334,000. Great Point Partners LLC increased its position in shares of Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after buying an additional 132,929 shares during the period. Finally, WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth about $265,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.